Survival after stem-cell transplant in pediatric and young-adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia
Authors:
- 24 October 2017
- journal article
- research article
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 34 (3) , 435-440
Abstract
Allogeneic stem-cell transplant (allo-SCT) is the standard of care for pediatric patients with acute lymphoblastic leukemia (ALL) who relapse after frontline chemotherapy; however, for patients who relapse after allo-SCT, outcomes are very poor. Few studies have examined overall survival in this patient population, particularly in patients who received a second allo-SCT. This was a retrospective analysis using data from the Center for International Blood and Marrow Transplant Research (CIBMTR) registry. The study population included patients aged 3 to 21 years who were diagnosed with B-ALL and underwent their first allo-SCT between 2009 and 2013. The primary endpoint was the time from the date of posttransplant relapse to the date of death due to any reason. Outcomes in 1349 pediatric and young-adult patients were included in this analysis. The Kaplan-Meier estimated probability of survival at 3 years after first allo-SCT was 63.1% (95% CI, 60.2%-65.8%). Overall, 29.2% of patients relapsed after first allo-SCT and had a median survival of 7.4 months (95% CI, 6.0-9.6 months). Twenty-five patients in the analysis developed secondary malignancies, most of which were lymphoproliferative disorders. Survival rates are low in pediatric and young-adult patients who relapse after first and second allo-SCT, and new therapies are needed to improve outcomes in this population. This data can be used as a historical comparison for single-arm trials of novel therapies for this patient population, including chimeric antigen receptor T-cell therapy.Keywords
This publication has 25 references indexed in Scilit:
- High-Risk Pediatric Acute Lymphoblastic Leukemia: To Transplant or Not to Transplant?Transplantation and Cellular Therapy, 2011
- Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant groupBlood, 2010
- Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983–2002: A Children's Oncology Group ReportLeukemia, 2009
- Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group studyLeukemia, 2008
- Lifetime Probabilities of Hematopoietic Stem Cell Transplantation in the U.S.Transplantation and Cellular Therapy, 2008
- Long-Term Outcome in Children With Relapsed ALL by Risk-Stratified Salvage Therapy: Results of Trial Acute Lymphoblastic Leukemia-Relapse Study of the Berlin-Frankfurt-Münster Group 87Journal of Clinical Oncology, 2005
- Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplantBone Marrow Transplantation, 2004
- Outcome of Cord-Blood Transplantation from Related and Unrelated DonorsNew England Journal of Medicine, 1997
- CD19 Antigen in Leukemia and Lymphoma Diagnosis and ImmunotherapyLeukemia & Lymphoma, 1995
- Second Neoplasms after Acute Lymphoblastic Leukemia in ChildhoodNew England Journal of Medicine, 1991